摘要:
This paper describes the lead optimization of a new series of potent, selective, orally bioavailable, brain-penetrant MCH-1 receptor antagonists. A major focus of the work was to achieve a selectivity pro. le appropriate for in vivo efficacy studies and safety. (c) 2008 Elsevier Ltd. All rights reserved.